文献速递甲状腺疾病

丹麦1997-2014年甲状腺髓样癌全国性研究:生存与长期生化治愈

Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study.
PubMed 文献 · Thyroid · 2019-01-31

该全国性回顾性队列研究纳入丹麦1997-2014年220例甲状腺髓样癌(MTC)患者,并与参考人群按50:1匹配,旨在识别生存率与一般人群相似的亚组及预测疾病特异性生存和长期生化治愈的预后因素。结果显示,筛查诊断的遗传性MTC、无区域淋巴结转移及I-III期患者总生存与参考人群相似;远处转移预测更差的疾病特异性生存,而无区域淋巴结转移是长期生化治愈的唯一独立预后因素。

要点

  • 筛查诊断的遗传性MTC、无区域淋巴结转移及I-III期患者总生存可能与一般人群相似。
  • 远处转移是疾病特异性生存的不良预后因素(HR=12.3)。
  • 无区域淋巴结转移是长期生化治愈的唯一独立预后因素(OR=40.1)。

核心结论

  • 筛查诊断的遗传性MTC、无区域淋巴结转移及I-III期患者总生存可能与一般人群相似。
  • 远处转移预测更差的疾病特异性生存,无区域淋巴结转移预测长期生化治愈。

研究设计与样本

  • 丹麦1997-2014年全国性回顾性队列研究,纳入220例MTC患者。
  • 参考人群按50:1与MTC队列匹配作为一般人群代表。

主要发现

  • 筛查诊断的遗传性MTC患者总生存与参考人群相似(HR=1.5 [CI 0.5-4.3])。
  • 无区域转移患者总生存与参考人群相似(HR=1.4 [CI 0.9-2.3])。
  • I期(HR=1.3 [CI 0.6-3.1])、II期(HR=1.1 [CI 0.6-2.3])、III期(HR=1.3 [CI 0.4-4.2])患者总生存与参考人群相似。
  • 多因素分析中,远处转移预测更差的疾病特异性生存(HR=12.3 [CI 6.0-25.0])。
  • 无区域淋巴结转移是长期生化治愈的唯一独立预后因素(OR=40.1 [CI 12.0-133.7])。

临床怎么用

  • 对遗传性MTC可通过筛查早期诊断,其生存可能与一般人群相似。
  • 无区域淋巴结转移及I-III期患者预后较好,但仍需长期随访。
  • 远处转移患者疾病特异性生存较差,应加强监测与治疗。
  • 无区域淋巴结转移提示长期生化治愈可能性高,可作为预后咨询依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival of medullary thyroid carcinoma (MTC) subgroups in relation to the general population is poorly described. Data on the factors predicting long-term biochemical cure in MTC patients are nonexistent at a population level. A nationwide retrospective cohort study of MTC in Denmark from 1997 to 2014 was conducted, aiming to detect subgroups with survival similar to that of the general population and to identify prognostic factors for disease-specific survival and long-term biochemical cure. METHODS: The study included 220 patients identified from the nationwide Danish MTC cohort between 1997 and 2014. As a representative sample of the general population, a reference population matched 50:1 to the MTC cohort was used. RESULTS: Patients diagnosed with hereditary MTC by screening (hazard ratio [HR] = 1.5 [confidence interval (CI) 0.5-4.3]), patients without regional metastases (HR = 1.4 [CI 0.9-2.3]), and patients with stage I (HR = 1.3 [CI 0.6-3.1]), stage II (HR = 1.1 [CI 0.6-2.3]), and III (HR = 1.3 [CI 0.4-4.2]) disease had an overall survival similar to the reference population. On multivariate analysis, the presence of distant metastases (HR = 12.3 [CI 6.0-25.0]) predicted worse disease-specific survival, while the absence of regional lymph node metastases (odds ratio = 40.1 [CI 12.0-133.7]) was the only independent prognostic factor for long-term biochemical cure. CONCLUSIONS: Patients with hereditary MTC diagnosed by screening, patients without regional metastases, and patients with stages I, II, and III disease may have similar survival as the general population. The presence of distant metastases predicted worse disease-specific survival, while the absence of regional metastases predicted long-term biochemical cure.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study. Thyroid. 2019. PMID: 30618340. doi:10.1089/thy.2018.0564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。